NCT00314106View on ClinicalTrials.gov

Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

March 31, 2009

Conditions
Metastatic Melanoma
Interventions
BIOLOGICAL

Melanoma Reactive TIL

DRUG

Cyclophosphamide

60 mg/kg/ day x 2 days intravenous

BIOLOGICAL

IL-2

720,000 IU/kg/dose every 8 hours for up to 15 doses

DRUG

Fludarabine

25 mg/m\^2/day intravenous x 5 days

RADIATION

1200 total body irradiation (TBI)

1200 cGY total body radiation

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00314106 - Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | Biotech Hunter | Biotech Hunter